Shiitake for Health & Longevity - Quick Reference Sheet

Shiitake for Health & Longevity

Created on 10/14/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 3.1 – Audit

Shiitake is an edible mushroom and oral supplement used to support immune defense and healthy blood fat levels. Human evidence for oral use is modest and mixed: whole mushrooms moderately lower blood triglycerides and shift white blood cells and salivary antibodies, whereas concentrated extracts show inconsistent effects. Thorough cooking and dicing prevent a temporary whip-like skin rash, elevated allergy-related white blood cells, and intestinal blockage. (Full Review)

Protocol

Whole culinary fruiting-body protocol
5–10 g/day dried (50–100 g/day fresh)
Thoroughly cooked; taken once daily with lunch or dinner
Standardized fruiting-body or mycelial β-glucan protocol
250–1,000 mg/day or 2.5 mg/day
Hot-water fruiting-body β-glucan extract or soluble mycelial β-glucan (Lentinex) once daily
Fermented mycelial alpha-glucan (AHCC) protocol
3 g/day (up to 9 g/day short-term)
Administered orally fasting in the morning or divided into 2–3 doses for up to 6 months
Time to effect
Serum Triglyceride Reduction
66 days
10% reduction (47.0 mg/dL net mean difference) with dried shiitake bars
Immune Cell Proliferation and Mucosal Defense
4 weeks
Increased lymphocyte proliferation and salivary sIgA with 5–10 g/day dried shiitake
Persistent Human Papillomavirus Clearance
6 months
Durable viral clearance with 3 g/day oral AHCC

Benefits

Contraindications
  • Individuals with prior shiitake flagellate dermatitis or Basidiomycota (club-fungi) mushroom allergy
  • Patients with eosinophilic gastrointestinal disorders or baseline peripheral blood eosinophilia
  • Individuals with intestinal strictures, Crohn's disease stenosis (luminal narrowing), or impaired mastication (for whole caps)
  • Clinical trial exclusion populations (for concentrated extracts): pregnancy or lactation, severe hypercholesterolemia (total cholesterol ≥ 300 mg/dL), chronic renal or hepatic failure
Key Interactions
  • OCTN1-transported prescription drugs (gabapentin, metformin, oxaliplatin)
  • CYP2D6-metabolized prescription drugs (doxorubicin, ondansetron, tamoxifen, metoprolol) (theoretical)
  • Aromatase inhibitors (letrozole, anastrozole, exemestane) (theoretical)
  • Over-the-counter CYP2D6 substrates (dextromethorphan, chlorpheniramine, diphenhydramine) (theoretical)
  • Lipid-lowering and immunomodulatory supplements (red yeast rice, plant sterols, Grifola frondosa [maitake mushroom], L-ergothioneine) (theoretical)
  • Immunosuppressive and checkpoint-inhibitor (immune-unblocking cancer drug) therapies (tacrolimus, cyclosporine, prednisone, nivolumab, ipilimumab) (theoretical)

Risk & Side Effects

  • High: Flagellate Dermatitis
  • Medium:
  • Low: Gastrointestinal Discomfort and Blood Eosinophilia, Mechanical Small Bowel Obstruction, Hypersensitivity Pneumonitis, Parenteral Infusion Reactions
  • Speculative: Endocrine Aromatase Induction and Cytochrome P450 2D6 Modulation

Monitoring

Marker Target Why
Fasting Serum Triglycerides No established target (percentage reduction from baseline) Expected to change: evaluates whether oral shiitake reduces circulating triglycerides
High-Sensitivity C-Reactive Protein (hs-CRP) No established target (reduction from baseline) Expected to change: assesses systemic inflammatory modulation reported with daily whole-mushroom intake
Salivary Secretory Immunoglobulin A (sIgA) No established target (increase from baseline) Expected to change: monitors mucosal immune response during daily dietary or β-glucan intake
Absolute Blood Eosinophil Count 0–400 cells/mm3 (standard reference range) Safety check: detects shiitake-induced blood eosinophilia that warrants stopping supplementation

Cadence: Baseline fasting lipid panel, hs-CRP, salivary sIgA, and complete blood count (CBC) with differential prior to initiation; CBC with differential repeated at 4 weeks (for unheated powders or high-dose extracts); fasting triglycerides, hs-CRP, and salivary sIgA assessed at 8–12 weeks and every 6 months thereafter.

Qualitative Assessment

  • Cutaneous tolerance: Absence of linear, pruritic rash within 72 hours of ingestion.
  • Gastrointestinal comfort: Stable stool habits without abdominal cramping, bloating, or nausea.
  • Upper respiratory resilience: Reduced frequency or severity of seasonal upper respiratory episodes over 3–6 months.